FDA watchdog admonishes Evofem for marketing brochure for its contraceptive Phexxinews2023-11-08T20:45:07+00:00November 8th, 2023|Endpoints News|
Teva says it’s actively searching for late-stage programs in next phase of growth strategynews2023-11-08T20:44:08+00:00November 8th, 2023|Endpoints News|
Moderna debuts first Spikevax brand campaign with lighthearted tone and catchy jinglenews2023-11-08T20:34:29+00:00November 8th, 2023|Endpoints News|
FDA approves an unbranded version of megablockbuster Humira, but AbbVie says it won’t ‘currently’ launchnews2023-11-08T20:09:29+00:00November 8th, 2023|Endpoints News|
Gilead’s HIV sales hit $4.7B in Q3, first six-month PrEP approval planned in 2025news2023-11-08T19:28:07+00:00November 8th, 2023|Endpoints News|
Senate Finance Committee unanimously advances PBM, Medicare Part D reformsnews2023-11-08T18:35:36+00:00November 8th, 2023|Endpoints News|
FDA+ roundup: Final guidance on the fastest oncology drug approvals; Remote inspections fail to take offnews2023-11-08T18:30:25+00:00November 8th, 2023|Endpoints News|
Updated: Eli Lilly’s tirzepatide breaks into obesity market with FDA approvalnews2023-11-08T17:52:41+00:00November 8th, 2023|Endpoints News|
Bayer to pull follicular lymphoma drug Aliqopa from US market in another blow to PI3K inhibitor spacenews2023-11-08T16:35:34+00:00November 8th, 2023|Endpoints News|
Lyell lays off 25% of staff and CMO leaves as company foreshadows first clinical data next yearnews2023-11-08T16:30:11+00:00November 8th, 2023|Endpoints News|
